# FDA Pre-Sub & Q-Sub: Meetings, Timelines & Guidance

Last reviewed: October 15, 2026

The FDA Q-Submission programs offer medical device companies a chance to communicate directly with the FDA about your device and regulatory strategy. These meetings allow you to ask targeted questions, get feedback, and avoid expensive delays in the regulatory process. Whether this is your first FDA interaction or you're preparing your tenth submission, Q-Subs give you a strategic edge.

Video guide

## FDA Pre-Sub: The Q-Submission Process

English audio · 1:45

Understand FDA Pre-Sub meetings, Q-Submission types, timelines and how to prepare focused questions.

[Open video page](https://www.pureglobal.com/videos/fda-pre-sub-q-submission-timeline)

Transcript (English)

How does an FDA Pre-Sub work? You send specific questions before a 510(k), De Novo, PMA or IDE, and FDA answers in writing, with an optional meeting. Here is the clock. A Pre-Sub is one type of Q-Submission. There is also the Submission Issue Request, after an FDA hold letter; the Study Risk Determination, for a planned clinical study; and the Informational Meeting, where FDA staff generally just listen. For a Pre-Sub, FDA runs its acceptance check within 15 days. Written feedback comes within 70 days, and at least 5 days before any meeting. Meetings usually land on day 70 to 75 and normally last one hour. Keep it small. FDA says the most effective Pre-Subs typically have no more than 7 to 10 questions, including sub-questions, across no more than four substantial topics. Start with three things. One: ask specific questions, not for a pre-review. Two: propose meeting dates around day 70. Three: send your draft meeting minutes within 15 days of the meeting. Fewer questions, sharper answers. Pure Global covers registration, in-country representation, quality systems, audits and cybersecurity, in more than 30 markets. Visit pureglobal.com.

Regulatory Overview

## FDA Q-Sub and Pre-Sub: choose the right interaction

The [US FDA](https://www.pureglobal.com/glossary/us-fda) Q-Submission program supports several interactions about device development and submissions. A Pre-Submission is one Q-Sub type, used to obtain feedback on focused questions before a future filing. It is voluntary, carries no FDA user fee and does not authorize marketing.

Use the [May 2025 final Q-Submission guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program) as the program reference. FDA’s electronic-template guidance and its current [eSTAR/PreSTAR program](https://www.fda.gov/medical-devices/how-study-and-market-your-device/estar-program) are separate resources; draft recommendations should not be described as a final mandatory rule.

| Q-Sub type | Appropriate purpose | Planning timeframe in the final guidance |
| --- | --- | --- |
| Pre-Submission | Feedback on a proposed evidence or submission strategy | Written feedback within 70 days or 5 days before the meeting, whichever is sooner; meeting usually around days 70–75 by agreement |
| Submission Issue Request | Discuss issues identified in an applicable FDA letter | 21 days as resources permit when received within 60 days of the letter; otherwise 70 days as resources permit |
| Study Risk Determination | Request FDA’s significant-risk/non-significant-risk assessment for a planned study | 90 days |
| Informational Meeting | Share information without requesting substantive feedback | 90 days |

These are program timeframes, not guaranteed outcomes or complete project schedules. Submission completeness, scope, FDA resources and mutual scheduling affect planning. Refer to the [guidance’s full table](https://www.fda.gov/media/114034/download) for qualifications and other request types.

## When is a Pre-Sub useful?

Use it before a consequential evidence decision: a novel clinical endpoint, unusual test method, complex predicate strategy or unresolved software-performance question. A clear concept, intended use and proposed approach let FDA give more useful feedback than an early request asking the agency to design the development program.

| Weak question | More useful formulation |
| --- | --- |
| What tests does FDA want? | Does FDA agree that the proposed test method and acceptance criteria address the identified failure mode for the stated use? |
| Will FDA clear our device? | Does FDA agree with the proposed comparison and evidence strategy, given the listed technological differences? |
| Is our study good enough? | Does FDA agree with the proposed endpoint, population and statistical rationale for the defined claim? |

These are illustrative drafting approaches, not FDA-approved question templates. Provide enough supporting material to let the reviewer assess the proposal. Use [classification work](https://www.pureglobal.com/markets/united-states/us-fda-medical-device-and-ivd-classification-consulting) first; a 513(g) request serves a different purpose and has a user fee.

## Prepare and submit a focused package

Include the Q-Sub type, device description, intended use, regulatory history, prior FDA interactions, proposed protocols, focused questions and your rationale. Group related questions into a manageable set of topics. Identify the desired feedback method and proposed meeting dates where relevant.

PreSTAR is available voluntarily for supported early submission types. It is not the same as the CDRH Portal, and Q-Subs should not all be described as mandatorily eSTAR. Follow the current center-specific channel and file instructions. Review the [eSTAR preparation guide](https://www.pureglobal.com/markets/united-states/fda-estar-submission-template-guide) for controlled attachments and format checks.

## Turn feedback into controlled evidence

Read written feedback before the meeting and use meeting time to clarify specific points. Identify the decisions that will change a protocol or submission plan. The submitter is responsible for drafting minutes and submitting them as an amendment, generally within 15 days of the meeting under the guidance. Preserve the written feedback and final minutes together.

Feedback is nonbinding and depends on the facts presented. Significant design changes, new evidence or changes in science can affect its relevance. Reference the Q-Sub in the later [510(k)](https://www.pureglobal.com/markets/united-states/us-fda-510k-clearance-submission-consulting), [De Novo](https://www.pureglobal.com/markets/united-states/fda-de-novo-classification-request) or [PMA](https://www.pureglobal.com/markets/united-states/fda-premarket-approval-pma-submission-consulting-for-medical-devices) and explain deviations from the discussed approach. Pure Global can scope the questions, prepare the package and convert the feedback into an evidence plan.

For a clinical program, assess the separate [IDE and Breakthrough designation decisions](https://www.pureglobal.com/markets/united-states/fda-ide-and-breakthrough-device-designation-guide) before finalizing study and marketing plans.

How We Can Help

## Expert Q-Sub and Pre-Sub Support from Pure Global

Plan your device registration, local representation and ongoing compliance with Pure Global.

[Contact us](https://www.pureglobal.com/contact)[Pricing](https://www.pureglobal.com/services/pricing?country=US)

![Pure Global market entry support team](https://www.pureglobal.com/assets/owned/75037ea614--67ab304f89cb5422fdc63bc7__67ab304f89cb5422fdc63d5e_feature_5.webp)

## Frequently asked questions

### Is FDA Pre-Submission feedback legally binding?

No. The feedback is nonbinding and based on the information presented. Keep later submissions consistent with that information and explain significant changes in design, evidence or the proposed approach.

### Can we submit a follow-up Pre-Sub for the same device?

Yes, when there are focused new or unresolved questions. Reference the earlier Q-Sub, summarize the change and avoid repeating broad questions without additional information or a proposed approach.

### Is a Pre-Sub mandatory before De Novo?

No. FDA recommends considering a Pre-Submission, particularly for a novel evidence strategy, but a De Novo request can be submitted directly if the applicable requirements are met.

### Is PreSTAR mandatory for every Q-Submission?

No. FDA currently offers PreSTAR voluntarily for supported early request types. Check the current program scope and the receiving center’s submission-channel instructions before preparing the package.

## Single Process,  
Multiple Markets

When you partner with Pure Global, a single registration process opens doors to multiple countries. Our global subsidiaries make this streamlined path possible.

[

Argentina



](https://www.pureglobal.com/markets/argentina)

[

Australia



](https://www.pureglobal.com/markets/australia)

[

Bangladesh



](https://www.pureglobal.com/markets/bangladesh)

[

Brazil



](https://www.pureglobal.com/markets/brazil)

[

Canada



](https://www.pureglobal.com/markets/canada)

[

China



](https://www.pureglobal.com/markets/china)

[

Colombia



](https://www.pureglobal.com/markets/colombia)

[

Costa Rica



](https://www.pureglobal.com/markets/costa-rica)

[

Egypt



](https://www.pureglobal.com/markets/egypt)

[

European Union



](https://www.pureglobal.com/markets/european-union)

[

Hong Kong



](https://www.pureglobal.com/markets/hong-kong)

[

India



](https://www.pureglobal.com/markets/india)

[

Indonesia



](https://www.pureglobal.com/markets/indonesia)

[

Israel



](https://www.pureglobal.com/markets/israel)

[

Japan



](https://www.pureglobal.com/markets/japan)

[

Macau



](https://www.pureglobal.com/markets/macau)

[

Malaysia



](https://www.pureglobal.com/markets/malaysia)

[

Mexico



](https://www.pureglobal.com/markets/mexico)

[

New Zealand



](https://www.pureglobal.com/markets/new-zealand)

[

Pakistan



](https://www.pureglobal.com/markets/pakistan)

[

Peru



](https://www.pureglobal.com/markets/peru)

[

Philippines



](https://www.pureglobal.com/markets/philippines)

[

Saudi Arabia



](https://www.pureglobal.com/markets/saudi-arabia)

[

Singapore



](https://www.pureglobal.com/markets/singapore)

[

South Korea



](https://www.pureglobal.com/markets/south-korea)

[

Switzerland



](https://www.pureglobal.com/markets/switzerland)

[

Taiwan



](https://www.pureglobal.com/markets/taiwan)

[

Thailand



](https://www.pureglobal.com/markets/thailand)

[

UAE



](https://www.pureglobal.com/markets/uae)

[

United Kingdom



](https://www.pureglobal.com/markets/united-kingdom)

[

United States



](https://www.pureglobal.com/markets/united-states)

[

Vietnam



](https://www.pureglobal.com/markets/vietnam)

[Canonical page](https://www.pureglobal.com/markets/united-states/fda-pre-sub-guidance-and-q-sub-guidance-for-medical-devices)
